Page 179 - Williams Hematology ( PDFDrive )

154 Part IV: Molecular and Cellular Hematology

REFERENCES 34. Ballabio A, Willard HF: Mammalian X-chromosome inactivation and the XIST gene.
Curr Opin Genet Dev 2:439–447, 1992.
1. Harrow J, Frankish A, Gonzalez JM, et al: GENCODE: The reference human genome 35. Esteller M: Epigenetics in cancer. N Engl J Med 358:1148–1159, 2008.
annotation for The ENCODE Project. Genome Res 22:1760–1774, 2012. 36. Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med 348:919–932,
2. Watson JD, Crick FHC: Molecular structure of nucleic acids: A structure for deoxyri- 2003.
bose nucleic acid. Nature 171:737, 1953. 37. Altshuler D, Daly MJ, Lander ES: Genetic mapping in human disease. Science 322:
3. Lewin B: Genes VIII. Prentice Hall, Englewood Cliffs, NJ, 2003. 881–888, 2008.
4. Roach JC, Glusman G, Smit AF, et al: Analysis of genetic inheritance in a family quartet 38. Durbin RM, Abecasis GR, Altshuler DL, et al: A map of human genome variation from
by whole-genome sequencing. Science 328:636–639, 2010. population-scale sequencing. Nature 467:1061–1073, 2010.
5. Campbell CD, Eichler EE: Properties and rates of germline mutations in humans. 39. Lander ES: Initial impact of the sequencing of the human genome. Nature 470:187–197,
Trends Genet 29:575–584, 2013. 2011.
6. Sudmant PH, Kitzman JO, Antonacci F, et al: Diversity of human copy number varia- 40. Lander ES, Linton LM, Birren B, et al: Initial sequencing and analysis of the human
tion and multicopy genes. Science 330:641–646, 2010. genome. Nature 409:860–921, 2001.
7. Mills RE, Walter K, Stewart C, et al: Mapping copy number variation by population-s- 41. Venter JC, Adams MD, Myers EW, et al: The sequence of the human genome. Science
cale genome sequencing. Nature 470:59–65, 2011. 291:1304–1351, 2001.
8. Taylor SM, Cerami C, Fairhurst RM: Hemoglobinopathies: Slicing the Gordian knot of 42. Davies K: The era of genomic medicine. Clin Med 13:594–601, 2013.
Plasmodium falciparum malaria pathogenesis. PLoS Pathog 9:e1003327, 2013. 43. Yang Y, Muzny DM, Reid JG, et al: Clinical whole-exome sequencing for the diagnosis
9. Kayser M, de Knijff P: Improving human forensics through advances in genetics, of mendelian disorders. N Engl J Med 369:1502–1511, 2013.
genomics and molecular biology. Nat Rev Genet 12:179–192, 2011. 44. White TJ, Arnheim N, Erlich HA: The polymerase chain reaction. Trends Genet 5:
10. Nelson DL, Orr HT, Warren ST: The unstable repeats—Three evolving faces of neuro- 185–190, 1989.
logical disease. Neuron 77:825–843, 2013. 45. Callaway E: Ancient DNA reveals secrets of human history. Nature 476:136–137, 2011.
11. Stankiewicz P, Lupski JR: Structural variation in the human genome and its role in 46. VanGuilder HD, Vrana KE, Freeman WM: Twenty-five years of quantitative PCR for
disease. Annu Rev Med 61:437–455, 2010. gene expression analysis. Biotechniques 44:619–626, 2008.
12. Zimran A, Gelbart T, Beutler E: Linkage of the PvuII polymorphism with the common 47. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors.
Jewish mutati. Am J Hum Genet 46:902–905, 1990. Proc Natl Acad Sci U S A 74:5463–5467, 1977.
13. Manoharan A: Congenital haptoglobin deficiency. Blood 90:1709, 1997. 48. Mardis ER: A decade’s perspective on DNA sequencing technology. Nature 470:
14. Jorde LB, Carey JC, Bamshad MJ: Medical Genetics, 4th ed. Mosby-Elsevier, St. Louis, 198–203, 2011.
2010. 49. Metzker ML: Sequencing technologies-the next generation. Nat Rev Genet 11:31–46,
15. Bennett RL, French KS, Resta RG, Doyle DL: Standardized human pedigree nomen- 2010.
clature: Update and assessment of the recommendations of the National Society of 50. Hayden EC: Technology: The $1,000 genome. Nature 507:294–295, 2014.
Genetic Counselors. J Genet Couns 17:424–433, 2008. 51. Koboldt DC, Steinberg KM, Larson DE, et al: The next-generation sequencing revolu-
16. Veltman JA, Brunner HG: De novo mutations in human genetic disease. Nat Rev Genet tion and its impact on genomics. Cell 155:27–38, 2013.
13:565–575, 2012. 52. Downward J: RNA interference. BMJ 328:1245–1248, 2004.
17. Biesecker LG, Spinner NB: A genomic view of mosaicism and human disease. Nat Rev 53. Marsden PA: RNA interference as potential therapy—not so fast. N Engl J Med 355:
Genet 14:307–320, 2013. 953–954, 2006.
18. Zlotogora J: Germ line mosaicism. Hum Genet 102:381–386, 1998. 54. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic lineage dif-
19. Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. Lancet 376:2018–2031, 2010. ferentiation. Science 303:83–86, 2004.
20. Khoury MJ, McCabe LL, McCabe ER: Population screening in the age of genomic med- 55. Heidenreich O, Eckstein F: Hammerhead ribozyme-mediated cleavage of the long terminal
icine. N Engl J Med 348:50–58, 2003. repeat RNA of human immunodeficiency virus type 1. J Biol Chem 267:1904–1909, 1992.
21. Bell CJ, Dinwiddie DL, Miller NA, et al: Carrier testing for severe childhood recessive 56. Soda Y, Tani K, Bai Y, et al: A novel maxizyme vector targeting a bcr-abl fusion gene
diseases by next-generation sequencing. Sci Transl Med 3:65ra4, 2011. induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic
22. Bodurtha J, Strauss JF: Genomics and perinatal care. N Engl J Med 366:64–73, 2012. leukemia. Blood 104:356–363, 2004.
23. Allen KJ, Gurrin LC, Constantine CC, et al: Iron-overload-related disease in HFE 57. Beuzard Y: Mouse models of sickle cell disease. Transfus Clin Biol 15:7–11, 2008.
hereditary hemochromatosis. N Engl J Med 358:221–230, 2008. 58. Zhou XY, Tomatsu S, Fleming RE, et al: HFE gene knockout produces mouse model of
24. Lettre G, Sankaran VG, Bezerra MA, et al: DNA polymorphisms at the BCL11A, hereditary hemochromatosis. Proc Natl Acad Sci U S A 95:2492–2497, 1998.
HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain cri- 59. Yu Y, Bradley A: Engineering chromosomal rearrangements in mice. Nat Rev Genet
ses in sickle cell disease. Proc Natl Acad Sci U S A 105:11869–11874, 2008. 2:780–790, 2001.
25. Lane DA, Grant PJ: Role of hemostatic gene polymorphisms in venous and arterial 60. Melis MA, Cau M, Congiu R, et al: A mutation in the TMPRSS6 gene, encoding a
thrombotic disease. Blood 95:1517–1532, 2000. transmembrane serine protease that suppresses hepcidin production, in familial iron
26. Bolton-Maggs PHB, Pasi KJ: Haemophilias A and B. Lancet 361:1801–1809, 2003. deficiency anemia refractory to oral iron. Haematologica 93:1473–1479, 2008.
27. Graw J, Brackmann HH, Oldenburg J, et al: Haemophilia A: From mutation analysis to 61. Cavazzana-Calvo M, Fischer A, Hacein-Bey-Abina S, Aiuti A: Gene therapy for pri-
new therapies. Nat Rev Genet 6:488–501, 2005. mary immunodeficiencies: Part 1. Curr Opin Immunol 24:580–584, 2012.
28. Adams PC, Barton JC: Haemochromatosis. Lancet 370:1855–1860, 2007. 62. Wirth T, Parker N, Yla-Herttuala S: History of gene therapy. Gene 525:162–169, 2013.
29. Lyon MF: X chromosomes and dosage compensation. Nature 320:313–330, 1986. 63. Kay MA: State-of-the-art gene-based therapies: The road ahead. Nat Rev Genet 12:
30. Lyon MF: Some milestones in the history of X-chromosome inactivation. Annu Rev 316–328, 2011.
Genet 26:17–28, 1992. 64. Nathwani AC, Tuddenham EGD, Rangarajan S, et al: Adenovirus-associated virus vec-
31. Wutz A, Gribnau J: X inactivation Xplained. Curr Opin Genet Dev 17:387–393, 2007. tor–mediated gene transfer in hemophilia B. N Engl J Med 365:2357–2365, 2011.
32. Lee JT, Bartolomei MS: X-inactivation, imprinting, and long noncoding RNAs in health 65. High KA: The gene therapy journey for hemophilia: Are we there yet? Blood 120:
and disease. Cell 152:1308–1323, 2013. 4482–4487, 2012.
33. Deng X, Berletch JB, Nguyen DK, Disteche CM: X chromosome regulation: Diverse 66. Ginn SL, Alexander IE, Edelstein ML, et al: Gene therapy clinical trials worldwide to
patterns in development, tissues and disease. Nat Rev Genet 15:367–378, 2014. 2012—An update. J Gene Med 15:65–77, 2013.

Kaushansky_chapter 10_p0143-0154.indd 154 9/18/15 10:23 PM